Production (Stage)
Regen BioPharma, Inc.
RGBP
$0.07
$0.028970.32%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.17% | 0.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.17% | 0.47% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.17% | 0.47% |
| SG&A Expenses | 16.50% | -29.56% | -34.55% | -38.37% | -38.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.85% | -29.12% | -34.79% | -35.37% | -37.54% |
| Operating Income | -3.18% | 39.11% | 46.12% | 47.35% | 50.38% |
| Income Before Tax | -65.50% | -157.28% | -151.48% | -101.01% | -143.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.50% | -157.28% | -151.48% | -101.01% | -143.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.50% | -157.28% | -151.48% | -101.01% | -143.51% |
| EBIT | -3.18% | 39.11% | 46.12% | 47.35% | 50.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -73.19% | -166.22% | -160.42% | -101.08% | -113.85% |
| Normalized Basic EPS | -65.86% | -158.68% | -175.38% | -101.04% | -113.73% |
| EPS Diluted | -73.19% | -166.22% | -160.42% | -101.08% | -113.85% |
| Normalized Diluted EPS | -65.86% | -158.68% | -175.38% | -101.04% | -113.73% |
| Average Basic Shares Outstanding | 35.44% | 16.36% | 23.23% | 17.89% | -15.70% |
| Average Diluted Shares Outstanding | 35.44% | 16.36% | 23.23% | 17.89% | -15.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |